Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016 (2016), Article ID 9850690, 12 pages
http://dx.doi.org/10.1155/2016/9850690
Review Article

Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future Perspective

1Department of Pathology, Penn State College of Medicine, Milton S. Hershey Medical Center, Hershey, PA, USA
2Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Received 31 May 2016; Accepted 10 August 2016

Academic Editor: Gokce Toruner

Copyright © 2016 Guoli Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Ferlay, I. Soerjomataram, R. Dikshit et al., “Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012,” International Journal of Cancer, vol. 136, no. 5, pp. E359–E386, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Siegel, C. Desantis, and A. Jemal, “Colorectal cancer statistics, 2014,” CA: A Cancer Journal for Clinicians, vol. 64, no. 2, pp. 104–117, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. H. Gharwan and H. Groninger, “Kinase inhibitors and monoclonal antibodies in oncology: clinical implications,” Nature Reviews Clinical Oncology, vol. 13, pp. 209–227, 2016. View at Publisher · View at Google Scholar · View at Scopus
  4. J. A. Sosman, K. B. Kim, L. Schuchter et al., “Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib,” The New England Journal of Medicine, vol. 366, no. 8, pp. 707–714, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Hauschild, J.-J. Grob, L. V. Demidov et al., “Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial,” The Lancet, vol. 380, no. 9839, pp. 358–365, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. K. T. Flaherty, C. Robert, P. Hersey et al., “Improved survival with MEK inhibition in BRAF-mutated melanoma,” The New England Journal of Medicine, vol. 367, no. 2, pp. 107–114, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. W. De Roock, B. Claes, D. Bernasconi et al., “Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis,” The Lancet Oncology, vol. 11, no. 8, pp. 753–762, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. J.-Y. Douillard, K. S. Oliner, S. Siena et al., “Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer,” The New England Journal of Medicine, vol. 369, no. 11, pp. 1023–1034, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. T. J. Lynch, D. W. Bell, R. Sordella et al., “Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib,” The New England Journal of Medicine, vol. 350, no. 21, pp. 2129–2139, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. J. G. Paez, P. A. Jänne, J. C. Lee et al., “EGFR mutations in lung, cancer: correlation with clinical response to gefitinib therapy,” Science, vol. 304, no. 5676, pp. 1497–1500, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. E. L. Kwak, Y.-J. Bang, D. R. Camidge et al., “Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer,” The New England Journal of Medicine, vol. 363, no. 18, pp. 1693–1703, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. C. J. Allegra, J. M. Jessup, M. R. Somerfield et al., “American society of clinical oncology provisional clinical opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy,” Journal of Clinical Oncology, vol. 27, no. 12, pp. 2091–2096, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. V. L. Keedy, S. Temin, M. R. Somerfield et al., “American Society of clinical oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy,” Journal of Clinical Oncology, vol. 29, no. 15, pp. 2121–2127, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. M. J. Sorich, M. D. Wiese, A. Rowland, G. Kichenadasse, R. A. McKinnon, and C. S. Karapetis, “Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials,” Annals of Oncology, vol. 26, no. 1, pp. 13–21, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. L. S. Schwartzberg, F. Rivera, M. Karthaus et al., “PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 32, no. 21, pp. 2240–2247, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. C. J. Allegra, R. Bryan Rumble, and R. L. Schilsky, “Extended RAS gene mutation testing in metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy: American society of clinical oncology provisional clinical opinion update 2015 summary,” Journal of Oncology Practice, vol. 12, no. 2, pp. 180–181, 2016. View at Publisher · View at Google Scholar · View at Scopus
  17. N. A. C. S. Wong, D. Gonzalez, M. Salto-Tellez et al., “RAS testing of colorectal carcinoma—a guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Group,” Journal of Clinical Pathology, vol. 67, no. 9, pp. 751–757, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. H. Taniguchi, K. Yamazaki, T. Yoshino et al., “Japanese Society of Medical Oncology Clinical Guidelines: RAS (KRAS/NRAS) mutation testing in colorectal cancer patients,” Cancer Science, vol. 106, no. 3, pp. 324–327, 2015. View at Publisher · View at Google Scholar · View at Scopus
  19. E. Van Cutsem, A. Cervantes, R. Adam et al., “ESMO consensus guidelines for the management of patients with metastatic colorectal cancer,” Annals of Oncology, vol. 27, no. 8, pp. 1386–1422, 2016. View at Publisher · View at Google Scholar
  20. F. Di Nicolantonio, M. Martini, F. Molinari et al., “Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 26, no. 35, pp. 5705–5712, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. C. Bokemeyer, E. V. Cutsem, P. Rougier et al., “Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials,” European Journal of Cancer, vol. 48, no. 10, pp. 1466–1475, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. F. Pietrantonio, F. Petrelli, A. Coinu et al., “Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis,” European Journal of Cancer, vol. 51, no. 5, article no. 9390, pp. 587–594, 2015. View at Publisher · View at Google Scholar · View at Scopus
  23. G. Cathomas, “PIK3CA in colorectal cancer,” Frontiers in Oncology, vol. 4, article 35, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. N. I. Lindeman, P. T. Cagle, M. B. Beasley et al., “Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology,” Journal of Thoracic Oncology, vol. 8, no. 7, pp. 823–859, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. N. I. Lindeman, P. T. Cagle, M. B. Beasley et al., “Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the study of lung cancer, and Association for Molecular Pathology,” Archives of Pathology and Laboratory Medicine, vol. 137, no. 6, pp. 828–860, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. N. I. Lindeman, P. T. Cagle, M. B. Beasley et al., “Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology,” The Journal of Molecular Diagnostics, vol. 15, no. 4, pp. 415–453, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. N. B. Leighl, N. Rekhtman, W. A. Biermann et al., “Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline,” Journal of Clinical Oncology, vol. 32, no. 32, pp. 3673–3679, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Dudley, L.-H. Tseng, L. Rooper et al., “Challenges posed to pathologists in the detection of KRAS mutations in colorectal cancers,” Archives of Pathology and Laboratory Medicine, vol. 139, no. 2, pp. 211–218, 2015. View at Publisher · View at Google Scholar · View at Scopus
  29. J. L. Hunt and S. D. Finkelstein, “Microdissection techniques for molecular testing in surgical pathology,” Archives of Pathology & Laboratory Medicine, vol. 128, no. 12, pp. 1372–1378, 2004. View at Google Scholar · View at Scopus
  30. J. H. J. M. Van Krieken, A. Jung, T. Kirchner et al., “KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program,” Virchows Archiv, vol. 453, no. 5, pp. 417–431, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. G. Zheng, H. Tsai, L. Tseng et al., “Test feasibility of next-generation sequencing assays in clinical mutation detection of small biopsy and fine needle aspiration specimens,” American Journal of Clinical Pathology, vol. 145, no. 5, pp. 696–702, 2016. View at Publisher · View at Google Scholar
  32. V. M. Singh, R. C. Salunga, V. J. Huang et al., “Analysis of the effect of various decalcification agents on the quantity and quality of nucleic acid (DNA and RNA) recovered from bone biopsies,” Annals of Diagnostic Pathology, vol. 17, no. 4, pp. 322–326, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. T. Reineke, B. Jenni, M.-T. Abdou et al., “Ultrasonic decalcification offers new perspectives for rapid FISH, DNA, and RT-PCR analysis in bone marrow trephines,” The American Journal of Surgical Pathology, vol. 30, no. 7, pp. 892–896, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. C. L. Wickham, P. Sarsfield, M. V. Joyner, D. B. Jones, S. Ellard, and B. Wilkins, “Formic acid decalcification of bone marrow trephines degrades DNA: alternative use of EDTA allows the amplification and sequencing of relatively long PCR products,” Molecular Pathology, vol. 53, no. 6, p. 336, 2000. View at Google Scholar
  35. G. Zheng, M. Lin, P. M. Lokhandwala et al., “Clinical mutational profiling of bone metastases of lung and colon carcinoma and malignant melanoma using next-generation sequencing,” Cancer Cytopathology, 2016. View at Publisher · View at Google Scholar
  36. L. Haley, L.-H. Tseng, G. Zheng et al., “Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers,” Modern Pathology, vol. 28, no. 10, pp. 1390–1399, 2015. View at Publisher · View at Google Scholar · View at Scopus
  37. G. M. Frampton, A. Fichtenholtz, G. A. Otto et al., “Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing,” Nature Biotechnology, vol. 31, no. 11, pp. 1023–1031, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. B. Angulo, E. García-García, R. Martínez et al., “A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: a morphology-based approach in colorectal carcinoma,” The Journal of Molecular Diagnostics, vol. 12, no. 3, pp. 292–299, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. J. Tol, J. R. Dijkstra, M. E. Vink-Börger et al., “High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue,” Journal of Cellular and Molecular Medicine, vol. 14, no. 8, pp. 2122–2131, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. W. Weichert, C. Schewe, A. Lehmann et al., “KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology,” The Journal of Molecular Diagnostics, vol. 12, no. 1, pp. 35–42, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. S. L. Ondrejka, D. F. Schaeffer, M. A. Jakubowski, D. A. Owen, and M. P. Bronner, “Does neoadjuvant therapy alter KRAS and/or MSI results in rectal adenocarcinoma testing?” The American Journal of Surgical Pathology, vol. 35, no. 9, pp. 1327–1330, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. F. Boissière-Michot, E. Lopez-Crapez, H. Frugier et al., “KRAS genotyping in rectal adenocarcinoma specimens with low tumor cellularity after neoadjuvant treatment,” Modern Pathology, vol. 25, no. 5, pp. 731–739, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. J. C. Dudley, G. T. Gurda, L.-H. Tseng et al., “Tumor cellularity as a quality assurance measure for accurate clinical detection of braf mutations in melanoma,” Molecular Diagnosis and Therapy, vol. 18, no. 4, pp. 409–418, 2014. View at Publisher · View at Google Scholar · View at Scopus
  44. L. A. Diaz Jr., R. T. Williams, J. Wu et al., “The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers,” Nature, vol. 486, no. 7404, pp. 537–540, 2012. View at Publisher · View at Google Scholar · View at Scopus
  45. P. Laurent-Puig, D. Pekin, C. Normand et al., “Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy,” Clinical Cancer Research, vol. 21, no. 5, pp. 1087–1097, 2015. View at Publisher · View at Google Scholar · View at Scopus
  46. H. Viray, K. Li, T. A. Long et al., “A prospective, multi-Institutional diagnostic trial to determine pathologist accuracy in estimation of percentage of malignant cells,” Archives of Pathology & Laboratory Medicine, vol. 137, no. 11, pp. 1545–1549, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. A. J. J. Smits, J. A. Kummer, P. C. De Bruin et al., “The estimation of tumor cell percentage for molecular testing by pathologists is not accurate,” Modern Pathology, vol. 27, no. 2, pp. 168–174, 2014. View at Publisher · View at Google Scholar · View at Scopus
  48. G. Chen, J. Dudley, L.-H. Tseng et al., “Lymph node metastases of melanoma: challenges for BRAF mutation detection,” Human Pathology, vol. 46, no. 1, pp. 113–119, 2015. View at Publisher · View at Google Scholar · View at Scopus
  49. S. Anderson, K. J. Bloom, D. U. Vallera et al., “Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin- embedded tissue specimens of malignant melanoma,” Archives of Pathology and Laboratory Medicine, vol. 136, no. 11, pp. 1385–1391, 2012. View at Publisher · View at Google Scholar · View at Scopus
  50. H. Halait, K. Demartin, S. Shah et al., “Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma,” Diagnostic Molecular Pathology, vol. 21, no. 1, pp. 1–8, 2012. View at Publisher · View at Google Scholar · View at Scopus
  51. C. T. Harbison, C. E. Horak, J.-M. Ledeine et al., “Validation of companion diagnostic for detection of mutations in codons 12 and 13 of the KRAS gene in patients with metastatic colorectal cancer: analysis of the NCIC CTG CO.17 trial,” Archives of Pathology & Laboratory Medicine, vol. 137, no. 6, pp. 820–827, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. A. Harlé, B. Busser, M. Rouyer et al., “Comparison of COBAS 4800 KRAS, TaqMan PCR and High Resolution Melting PCR assays for the detection of KRAS somatic mutations in formalin-fixed paraffin embedded colorectal carcinomas,” Virchows Archiv, vol. 462, no. 3, pp. 329–335, 2013. View at Publisher · View at Google Scholar · View at Scopus
  53. A. C. Tsiatis, A. Norris-Kirby, R. G. Rich et al., “Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications,” The Journal of Molecular Diagnostics, vol. 12, no. 4, pp. 425–432, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. H. Do, M. Krypuy, P. L. Mitchell, S. B. Fox, and A. Dobrovic, “High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies,” BMC Cancer, vol. 8, article 142, 2008. View at Publisher · View at Google Scholar · View at Scopus
  55. T. Kobunai, T. Watanabe, Y. Yamamoto, and K. Eshima, “The frequency of KRAS mutation detection in human colon carcinoma is influenced by the sensitivity of assay methodology: a comparison between direct sequencing and real-time PCR,” Biochemical and Biophysical Research Communications, vol. 395, no. 1, pp. 158–162, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. K. Oliner, T. Juan, S. Suggs et al., “A comparability study of 5 commercial KRAS tests,” Diagnostic Pathology, vol. 5, article 23, 2010. View at Publisher · View at Google Scholar · View at Scopus
  57. P. Szankasi, N. S. Reading, C. P. Vaughn, J. T. Prchal, D. W. Bahler, and T. W. Kelley, “A quantitative allele-specific PCR test for the BRAF V600E mutation using a single heterozygous control plasmid for quantitation: a model for qPCR testing without standard curves,” The Journal of Molecular Diagnostics, vol. 15, no. 2, pp. 248–254, 2013. View at Publisher · View at Google Scholar · View at Scopus
  58. G. V. Long, J. S. Wilmott, D. Capper et al., “Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma,” American Journal of Surgical Pathology, vol. 37, no. 1, pp. 61–65, 2013. View at Publisher · View at Google Scholar · View at Scopus
  59. C. A. Routhier, M. C. Mochel, K. Lynch, D. Dias-Santagata, D. N. Louis, and M. P. Hoang, “Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas,” Human Pathology, vol. 44, no. 11, pp. 2563–2570, 2013. View at Publisher · View at Google Scholar · View at Scopus
  60. R. Dienstmann, J. Rodon, J. Barretina, and J. Tabernero, “Genomic medicine frontier in human solid tumors: prospects and challenges,” Journal of Clinical Oncology, vol. 31, no. 15, pp. 1874–1884, 2013. View at Publisher · View at Google Scholar · View at Scopus
  61. K. K. Deeb, J. P. Sram, H. Gao, and M. G. Fakih, “Multigene assays in metastatic colorectal cancer,” Journal of the National Comprehensive Cancer Network, vol. 11, supplement 4, pp. S9–S17, 2013. View at Google Scholar · View at Scopus
  62. W. O. Greaves, S. Verma, K. P. Patel et al., “Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma,” Journal of Molecular Diagnostics, vol. 15, no. 2, pp. 220–226, 2013. View at Publisher · View at Google Scholar · View at Scopus
  63. S. Magnin, E. Viel, A. Baraquin et al., “A multiplex SNaPshot assay as a rapid method for detecting KRAS and BRAF mutations in advanced colorectal cancers,” The Journal of Molecular Diagnostics, vol. 13, no. 5, pp. 485–492, 2011. View at Publisher · View at Google Scholar · View at Scopus
  64. A. S. Gargis, L. Kalman, M. W. Berry et al., “Assuring the quality of next-generation sequencing in clinical laboratory practice,” Nature Biotechnology, vol. 30, no. 11, pp. 1033–1036, 2012. View at Publisher · View at Google Scholar · View at Scopus
  65. A. S. Gargis, L. Kalman, D. P. Bick et al., “Good laboratory practice for clinical next-generation sequencing informatics pipelines,” Nature Biotechnology, vol. 33, no. 7, pp. 689–693, 2015. View at Publisher · View at Google Scholar · View at Scopus
  66. N. Aziz, Q. Zhao, L. Bry et al., “College of American pathologists' laboratory standards for next-generation sequencing clinical tests,” Archives of Pathology & Laboratory Medicine, vol. 139, no. 4, pp. 481–493, 2015. View at Publisher · View at Google Scholar · View at Scopus
  67. M.-T. Lin, S. L. Mosier, M. Thiess et al., “Clinical validation of KRAS, BRAF, and EGFR mutation detection using next-generation sequencing,” American Journal of Clinical Pathology, vol. 141, no. 6, pp. 856–866, 2014. View at Publisher · View at Google Scholar · View at Scopus
  68. A. G. Hadd, J. Houghton, A. Choudhary et al., “Targeted, high-depth, next-generation sequencing of cancer genes in formalin-fixed, paraffin-embedded and fine-needle aspiration tumor specimens,” Journal of Molecular Diagnostics, vol. 15, no. 2, pp. 234–247, 2013. View at Publisher · View at Google Scholar · View at Scopus
  69. R. R. Singh, K. P. Patel, M. J. Routbort et al., “Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes,” The Journal of Molecular Diagnostics, vol. 15, no. 5, pp. 607–622, 2013. View at Publisher · View at Google Scholar · View at Scopus
  70. C. E. Cottrell, H. Al-Kateb, A. J. Bredemeyer et al., “Validation of a next-generation sequencing assay for clinical molecular oncology,” The Journal of Molecular Diagnostics, vol. 16, no. 1, pp. 89–105, 2014. View at Publisher · View at Google Scholar · View at Scopus
  71. C. C. Pritchard, S. J. Salipante, K. Koehler et al., “Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens,” The Journal of Molecular Diagnostics, vol. 16, no. 1, pp. 56–67, 2014. View at Publisher · View at Google Scholar · View at Scopus
  72. H. Beltran, K. Eng, J. M. Mosquera et al., “Whole-exome sequencing of metastatic cancer and biomarkers of treatment response,” JAMA Oncology, vol. 1, no. 4, pp. 466–474, 2015. View at Publisher · View at Google Scholar
  73. D. W. Parsons, A. Roy, Y. Yang et al., “Diagnostic yield of clinical tumor and germline whole-exome sequencing for children with solid tumors,” JAMA Oncology, vol. 2, no. 5, pp. 616–624, 2016. View at Publisher · View at Google Scholar
  74. J. Carter, L.-H. Tseng, G. Zheng et al., “Non-p.V600E BRAF mutations are common using a more sensitive and broad detection tool,” American Journal of Clinical Pathology, vol. 144, no. 4, pp. 620–628, 2015. View at Publisher · View at Google Scholar · View at Scopus
  75. G. Zheng, L.-H. Tseng, G. Chen et al., “Clinical detection and categorization of uncommon and concomitant mutations involving BRAF,” BMC Cancer, vol. 15, article 779, 2015. View at Publisher · View at Google Scholar · View at Scopus
  76. P. T. C. Wan, M. J. Garnett, S. M. Roe et al., “Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF,” Cell, vol. 116, no. 6, pp. 855–867, 2004. View at Publisher · View at Google Scholar · View at Scopus
  77. S. J. Heidorn, C. Milagre, S. Whittaker et al., “Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF,” Cell, vol. 140, no. 2, pp. 209–221, 2010. View at Publisher · View at Google Scholar · View at Scopus
  78. A. N. Bartley and S. R. Hamilton, “Select biomarkers for tumors of the gastrointestinal tract: present and future,” Archives of Pathology & Laboratory Medicine, vol. 139, no. 4, pp. 457–468, 2015. View at Publisher · View at Google Scholar · View at Scopus
  79. G. Deng, I. Bell, S. Crawley et al., “BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer,” Clinical Cancer Research, vol. 10, no. 1 I, pp. 191–195, 2004. View at Publisher · View at Google Scholar · View at Scopus
  80. W. K. Funkhouser Jr., I. M. Lubin, F. A. Monzon et al., “Relevance, Pathogenesis, and testing algorithm for mismatch repair-defective colorectal carcinomas: a report of the association for molecular pathology,” Journal of Molecular Diagnostics, vol. 14, no. 2, pp. 91–103, 2012. View at Publisher · View at Google Scholar · View at Scopus
  81. P. Lochhead, A. Kuchiba, Y. Imamura et al., “Microsatellite instability and braf mutation testing in colorectal cancer prognostication,” Journal of the National Cancer Institute, vol. 105, no. 15, pp. 1151–1156, 2013. View at Publisher · View at Google Scholar · View at Scopus
  82. A. I. Phipps, P. J. Limburg, J. A. Baron et al., “Association between molecular subtypes of colorectal cancer and patient survival,” Gastroenterology, vol. 148, no. 1, pp. 77.e2–87.e2, 2015. View at Publisher · View at Google Scholar · View at Scopus
  83. S. Venderbosch, I. D. Nagtegaal, T. S. Maughan et al., “Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies,” Clinical Cancer Research, vol. 20, no. 20, pp. 5322–5330, 2014. View at Publisher · View at Google Scholar · View at Scopus
  84. S. Popat, R. Hubner, and R. S. Houlston, “Systematic review of microsatellite instability and colorectal cancer prognosis,” Journal of Clinical Oncology, vol. 23, no. 3, pp. 609–618, 2005. View at Publisher · View at Google Scholar · View at Scopus
  85. J. Goldstein, B. Tran, J. Ensor et al., “Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H),” Annals of Oncology, vol. 25, no. 5, pp. 1032–1038, 2014. View at Publisher · View at Google Scholar · View at Scopus
  86. C. M. Ribic, D. J. Sargent, M. J. Moore et al., “Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer,” The New England Journal of Medicine, vol. 349, no. 3, pp. 247–257, 2003. View at Publisher · View at Google Scholar · View at Scopus
  87. J. M. Carethers, E. J. Smith, C. A. Behling et al., “Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer,” Gastroenterology, vol. 126, no. 2, pp. 394–401, 2004. View at Publisher · View at Google Scholar · View at Scopus
  88. D. J. Sargent, S. Marsoni, G. Monges et al., “Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer,” Journal of Clinical Oncology, vol. 28, no. 20, pp. 3219–3226, 2010. View at Publisher · View at Google Scholar · View at Scopus
  89. F. A. Sinicrope, N. R. Foster, S. N. Thibodeau et al., “DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy,” Journal of the National Cancer Institute, vol. 103, no. 11, pp. 863–875, 2011. View at Publisher · View at Google Scholar · View at Scopus
  90. E. M. Webber, T. L. Kauffman, E. O'Connor, and K. A. Goddard, “Systematic review of the predictive effect of MSI status in colorectal cancer patients undergoing 5FU-based chemotherapy,” BMC Cancer, vol. 15, article 156, 2015. View at Publisher · View at Google Scholar · View at Scopus
  91. D. T. Le, J. N. Uram, H. Wang et al., “PD-1 blockade in tumors with mismatch-repair deficiency,” The New England Journal of Medicine, vol. 372, no. 26, pp. 2509–2520, 2015. View at Publisher · View at Google Scholar · View at Scopus
  92. C.-S. Tan, D. Gilligan, and S. Pacey, “Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer,” The Lancet Oncology, vol. 16, no. 9, pp. e447–e459, 2015. View at Publisher · View at Google Scholar · View at Scopus
  93. G. Siravegna, B. Mussolin, M. Buscarino et al., “Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients,” Nature Medicine, vol. 21, pp. 795–801, 2015. View at Publisher · View at Google Scholar
  94. S. Misale, S. Arena, S. Lamba et al., “Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer,” Science Translational Medicine, vol. 6, no. 224, Article ID 224ra26, 2014. View at Publisher · View at Google Scholar · View at Scopus
  95. C. Bettegowda, M. Sausen, R. J. Leary et al., “Detection of circulating tumor DNA in early- and late-stage human malignancies,” Science Translational Medicine, vol. 6, no. 224, 2014. View at Publisher · View at Google Scholar · View at Scopus
  96. S. Misale, R. Yaeger, S. Hobor et al., “Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer,” Nature, vol. 486, no. 7404, pp. 532–536, 2012. View at Publisher · View at Google Scholar · View at Scopus
  97. S. Misale, F. Di Nicolantonio, A. Sartore-Bianchi, S. Siena, and A. Bardelli, “Resistance to anti-EGFR therapy in colorectal cancer: From heterogeneity to convergent evolution,” Cancer Discovery, vol. 4, no. 11, pp. 1269–1280, 2014. View at Publisher · View at Google Scholar · View at Scopus
  98. G. Bronte, N. Silvestris, M. Castiglia et al., “New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?” Oncotarget, vol. 6, no. 28, pp. 24780–24796, 2015. View at Publisher · View at Google Scholar · View at Scopus
  99. M. Russo, G. Siravegna, L. S. Blaszkowsky et al., “Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer,” Cancer Discovery, vol. 6, no. 2, pp. 147–153, 2016. View at Publisher · View at Google Scholar · View at Scopus
  100. C. Montagut, A. Dalmases, B. Bellosillo et al., “Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer (vol 18, pg 221, 2012),” Nature Medicine, vol. 18, no. 9, p. 1445, 2012. View at Google Scholar
  101. S. Arena, G. Siravegna, B. Mussolin et al., “MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations,” Science Translational Medicine, vol. 8, no. 324, Article ID 324ra14, 2016. View at Publisher · View at Google Scholar · View at Scopus
  102. A. Bertotti, E. Papp, S. Jones et al., “The genomic landscape of response to EGFR blockade in colorectal cancer,” Nature, vol. 526, no. 7572, pp. 263–267, 2015. View at Publisher · View at Google Scholar · View at Scopus
  103. C. Esposito, A. M. Rachiglio, M. L. La Porta et al., “The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies,” Cancer Biology and Therapy, vol. 14, no. 12, pp. 1143–1146, 2013. View at Publisher · View at Google Scholar · View at Scopus
  104. M. Gerlinger, A. J. Rowan, S. Horswell et al., “Intratumor heterogeneity and branched evolution revealed by multiregion sequencing,” The New England Journal of Medicine, vol. 366, no. 10, pp. 883–892, 2012. View at Publisher · View at Google Scholar · View at Scopus
  105. R. A. Burrell, N. McGranahan, J. Bartek, and C. Swanton, “The causes and consequences of genetic heterogeneity in cancer evolution,” Nature, vol. 501, no. 7467, pp. 338–345, 2013. View at Publisher · View at Google Scholar · View at Scopus
  106. S. Maheswaran, L. V. Sequist, S. Nagrath et al., “Detection of mutations in EGFR in circulating lung-cancer cells,” The New England Journal of Medicine, vol. 359, no. 4, pp. 366–377, 2008. View at Publisher · View at Google Scholar · View at Scopus
  107. K.-Y. Su, H.-Y. Chen, K.-C. Li et al., “Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 30, no. 4, pp. 433–440, 2012. View at Publisher · View at Google Scholar · View at Scopus
  108. M. Furugen, K. Uechi, J. Hirai et al., “An autopsy case of two distinct, acquired drug resistance mechanisms in epidermal growth factor receptor-mutant lung adenocarcinoma: small cell carcinoma transformation and epidermal growth factor receptor T790M mutation,” Internal Medicine, vol. 54, no. 19, pp. 2491–2496, 2015. View at Publisher · View at Google Scholar · View at Scopus
  109. K. Suda, I. Murakami, K. Sakai et al., “Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer,” Scientific Reports, vol. 5, Article ID 14447, 2015. View at Publisher · View at Google Scholar · View at Scopus
  110. M. J. Niederst, L. V. Sequist, J. T. Poirier et al., “RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer,” Nature Communications, vol. 6, article 6377, 2015. View at Publisher · View at Google Scholar · View at Scopus
  111. A. Snyder, V. Makarov, T. Merghoub et al., “Genetic basis for clinical response to CTLA-4 blockade in melanoma,” The New England Journal of Medicine, vol. 371, no. 23, pp. 2189–2199, 2014. View at Publisher · View at Google Scholar · View at Scopus
  112. F. S. Hodi, S. J. O'Day, D. F. McDermott et al., “Improved survival with ipilimumab in patients with metastatic melanoma,” The New England Journal of Medicine, vol. 363, no. 8, pp. 711–723, 2010. View at Publisher · View at Google Scholar · View at Scopus
  113. C. Robert, L. Thomas, I. Bondarenko et al., “Ipilimumab plus dacarbazine for previously untreated metastatic melanoma,” The New England Journal of Medicine, vol. 364, no. 26, pp. 2517–2526, 2011. View at Publisher · View at Google Scholar · View at Scopus
  114. J. R. Brahmer, S. S. Tykodi, L. Q. M. Chow et al., “Safety and activity of anti-PD-L1 antibody in patients with advanced cancer,” The New England Journal of Medicine, vol. 366, no. 26, pp. 2455–2465, 2012. View at Publisher · View at Google Scholar · View at Scopus
  115. S. L. Topalian, F. S. Hodi, J. R. Brahmer et al., “Safety, activity, and immune correlates of anti-PD-1 antibody in cancer,” The New England Journal of Medicine, vol. 366, no. 26, pp. 2443–2454, 2012. View at Publisher · View at Google Scholar · View at Scopus
  116. T. Powles, J. P. Eder, G. D. Fine et al., “MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer,” Nature, vol. 515, no. 7528, pp. 558–562, 2014. View at Publisher · View at Google Scholar · View at Scopus
  117. E. de Guillebon, P. Roussille, E. Frouin, and D. Tougeron, “Anti program death-1/anti program death-ligand 1 in digestive cancers,” World Journal of Gastrointestinal Oncology, vol. 7, no. 8, pp. 95–101, 2015. View at Publisher · View at Google Scholar
  118. J. R. Eshleman, E. Z. Lang, G. K. Bowerfind et al., “Increased mutation rate at the hprt locus accompanies microsatellite instability in colon cancer,” Oncogene, vol. 10, no. 1, pp. 33–37, 1995. View at Google Scholar · View at Scopus
  119. N. J. Llosa, M. Cruise, A. Tam et al., “The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints,” Cancer Discovery, vol. 5, no. 1, pp. 43–51, 2015. View at Publisher · View at Google Scholar · View at Scopus
  120. F. Pagès, A. Berger, M. Camus et al., “Effector memory T cells, early metastasis, and survival in colorectal cancer,” The New England Journal of Medicine, vol. 353, no. 25, pp. 2654–2666, 2005. View at Publisher · View at Google Scholar · View at Scopus
  121. S. D. Brown, R. L. Warren, E. A. Gibb et al., “Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival,” Genome Research, vol. 24, no. 5, pp. 743–750, 2014. View at Publisher · View at Google Scholar · View at Scopus
  122. S. M. Ansell, A. M. Lesokhin, I. Borrello et al., “PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma,” The New England Journal of Medicine, vol. 372, no. 4, pp. 311–319, 2015. View at Publisher · View at Google Scholar · View at Scopus
  123. R. S. Herbst, J.-C. Soria, M. Kowanetz et al., “Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients,” Nature, vol. 515, no. 7528, pp. 563–567, 2014. View at Publisher · View at Google Scholar · View at Scopus
  124. F. Passiglia, G. Bronte, V. Bazan et al., “PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis,” Oncotarget, 2016. View at Publisher · View at Google Scholar
  125. N. A. Rizvi, M. D. Hellmann, A. Snyder et al., “Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer,” Science, vol. 348, no. 6230, pp. 124–128, 2015. View at Publisher · View at Google Scholar · View at Scopus
  126. E. M. Van Allen, D. Miao, B. Schilling et al., “Genomic correlates of response to CTLA-4 blockade in metastatic melanoma,” Science, vol. 350, no. 6257, pp. 207–211, 2015. View at Publisher · View at Google Scholar
  127. H. Dong, S. E. Strome, D. R. Salomao et al., “Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion,” Nature Medicine, vol. 8, no. 8, pp. 793–800, 2002. View at Google Scholar
  128. R. A. Droeser, C. Hirt, C. T. Viehl et al., “Clinical impact of programmed cell death ligand 1 expression in colorectal cancer,” European Journal of Cancer, vol. 49, no. 9, pp. 2233–2242, 2013. View at Publisher · View at Google Scholar · View at Scopus
  129. J. C. Dudley, M. Lin, D. T. Le, and J. R. Eshleman, “Microsatellite instability as a biomarker for PD-1 Blockade,” Clinical Cancer Research, vol. 22, no. 4, pp. 813–820, 2016. View at Publisher · View at Google Scholar
  130. S. A. Roberts and D. A. Gordenin, “Hypermutation in human cancer genomes: footprints and mechanisms,” Nature Reviews Cancer, vol. 14, no. 12, pp. 786–800, 2014. View at Publisher · View at Google Scholar · View at Scopus
  131. C. Palles, J. B. Cazier, K. M. Howarth et al., “Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas,” Nature Genetics, vol. 45, no. 2, pp. 136–144, 2013. View at Google Scholar
  132. L. Valle, E. Hernández-Illán, F. Bellido et al., “New insights into POLE and POLD1 germline mutations in familial colorectal cancer and polyposis,” Human Molecular Genetics, vol. 23, no. 13, pp. 3506–3512, 2014. View at Publisher · View at Google Scholar · View at Scopus
  133. S. Briggs and I. Tomlinson, “Germline and somatic polymerase ϵ and δ mutations define a new class of hypermutated colorectal and endometrial cancers,” The Journal of Pathology, vol. 230, no. 2, pp. 148–153, 2013. View at Publisher · View at Google Scholar · View at Scopus
  134. The Cancer Genome Atlas Network, “Comprehensive molecular characterization of human colon and rectal cancer,” Nature, vol. 487, no. 7407, pp. 330–337, 2012. View at Google Scholar
  135. E. Domingo, L. Freeman-Mills, E. Rayner et al., “Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study,” The Lancet Gastroenterology & Hepatology, 2016. View at Publisher · View at Google Scholar
  136. E. Stelloo, T. Bosse, R. A. Nout et al., “Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; A TransPORTEC initiative,” Modern Pathology, vol. 28, no. 6, pp. 836–844, 2015. View at Publisher · View at Google Scholar · View at Scopus
  137. M. K. McConechy, A. Talhouk, S. Leung et al., “Endometrial carcinomas with POLE exonuclease domain mutations have a favorable prognosis,” Clinical Cancer Research, vol. 22, no. 12, pp. 2865–2873, 2016. View at Publisher · View at Google Scholar
  138. I. C. Van Gool, F. A. Eggink, L. Freeman-Mills et al., “POLE proofreading mutations elicit an antitumor immune response in endometrial cancer,” Clinical Cancer Research, vol. 21, no. 14, pp. 3347–3355, 2015. View at Publisher · View at Google Scholar · View at Scopus
  139. E. I. Lin, L.-H. Tseng, C. D. Gocke et al., “Mutational profiling of colorectal cancers with microsatellite instability,” Oncotarget, vol. 6, no. 39, pp. 42334–42344, 2015. View at Publisher · View at Google Scholar · View at Scopus
  140. M. B. Atkins and J. Larkin, “Immunotherapy combined or sequenced with targeted therapy in the treatment of solid tumors: current perspectives,” Journal of the National Cancer Institute, vol. 108, no. 6, Article ID djv414, 2016. View at Publisher · View at Google Scholar